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1. Introduction
Lower urinary tract symptoms (LUTS) are defined by the 
International Continence Society as all urinary symptoms 
which occur during the phases of storage (increased 
daytime frequency, nocturia, urgency, and/or urinary in-
continence), voiding (terminal dribble, hesitancy, inter-
mittency, straining, and/or splitting/spraying/slow stream), 
and post-micturition (incomplete emptying or post-
micturition dribble).1 A population-based epidemiologic 
study using the 2002 International Continence Society 
definition showed that the prevalence of storage LUTS 
(men, 51.3%; women, 59.2%) was greater than that of 
voiding (men, 25.7%; women, 19.5%) and post-micturition 
(men, 16.9%; women, 14.2%) symptoms combined.2 LUTS 
in men may be related to bladder dysfunction or bladder 
outlet obstruction, which is often associated with be-
nign prostatic hyperplasia (BPH). Although α1 adrenergic 
receptor antagonists (α-blockers) and 5α-reductase in-
hibitors are helpful in treating LUTS associated with BPH 
(LUTS/BPH), some storage symptoms such as nocturia or 
urgency may be refractory to standard treatment. The 
benefit of antimuscarinics in alleviating these symptoms 
should be weighed against the risks of urinary retention 
or treatment-related side effects such as dry mouth and 
constipation.
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There are 2 CME questions based on this article
Erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) associated with 
benign prostatic hyperplasia (BPH) are two common diseases among men aged over 
50. Population or community-based epidemiologic studies have shown higher prev-
alence of male ED among men with LUTS associated with BPH. The exact mecha-
nisms are unclear, but nitric oxide/cyclic guanosine monophosphate signal may be 
involved in the common pathway in the pathogenesis via smooth muscle relaxation 
control. Phosphodiesterase type 5 (PDE5) inhibitors have become the mainstay 
treatment of choice for male ED since the launch of sildenafil citrate in 1998. 
However, more evidence has shown that men receiving PDE5 inhibitors for their ED 
treatment have also benefited from improvement on their LUTS. Early randomized 
clinical studies has shown that daily dosing with PDE5 inhibitors (sildenafil, tadalafil 
and vardenafil) could improve the irritative or obstructive symptoms based on re-
duction in the International Prostate Symptom Score but had little effect on uroflow 
rate or post-voiding residuals. The combined use of PDE5 inhibitors and α-blockers 
has revealed more promising results on LUTS alleviation, but the safety profiles of 
this kind of combined use should be further evaluated and confirmed by greater-
scale, randomized and comparative clinical studies.
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Since the launch of sildenafil citrate in 1998, phos-
phodiesterase type 5 (PDE5) inhibitors are extensively 
used as the first-line drug of choice for treating male 
erectile dysfunction (ED). With increasing evidence to 
support the close relationship between LUTS/BPH and 
ED, PDE5 inhibitors were used to treat LUTS in some pre-
liminary studies with favorable outcomes. This mini re-
view focuses on the rationale for using PDE5 inhibitors 
for LUTS/BPH treatment, updates clinical results regarding 
all three PDE5 inhibitors for LUTS/BPH treatment, and re-
views the safety profiles of their concomitant use with 
α-blockers based on a literature review.
2. ED and LUTS Associated With BPH
2.1.  Close Links Between ED and LUTS/
BPH—Epidemiologic Evidence
Since the 1990s, several population- or community-based 
epidemiologic studies have shown that urinary symptoms 
might have direct impact on sexual dysfunction and sat-
isfaction with one’s sexual life.3–6 In a large, community-
based study conducted in France involving 2011 men 
aged 50–80 years, Macfarlane et al.3 found that the se-
verity of overall urinary symptoms was inversely related 
to satisfaction with one’s sexual life, and the association 
persisted after adjusting for various factors of age and 
the frequency of sexual relations.3 In a multinational study 
involving 423 men aged ≥ 40 years in a community popu-
lation in the UK and 1271 people visiting a urology clinic 
aged ≥ 45 years in 12 countries, the authors found that 
patients with LUTS, especially those with storage symp-
toms associated with incontinence had a higher odds 
ratio for sexual dysfunction.4 Braun et al.5 found that the 
prevalence of LUTS in men suffering from ED was about 
72.2% (n = 621) versus 37.7% (n = 1367) in men with nor-
mal erections. The occurrence of LUTS can be consid-
ered an age-independent risk factor for the development 
of ED with an odds ratio of 2.11 (p < 0.001).5 In a multi-
national survey involving 12,825 men aged 50–80 years, 
sexual disorders and their impact on quality of life were 
strongly related to both age and the severity of LUTS. 
The relationship between sexual disorders and LUTS 
was independent of comorbidities including diabetes, 
hypertension, cardiac disease, and hypercholesterolemia.6 
Recently, a population-based, cross-sectional internet sur-
vey enrolling 30,000 men and women aged > 40 years 
was conducted in the US (n = 20,000), the UK (n = 7500), 
and Sweden (n = 2500). Among 11,834 men with a mean 
age of 56.1 years, 71% reported being currently sexually 
active, and 26% of these sexually active men had mild to 
severe ED, 7% had ejaculation disorders, and 16% had 
premature ejaculation. ED was associated with an older 
age, hypertension, diabetes, depression, and LUTS includ-
ing urgency with fear of leaking, a weak stream, a split 
stream, leaking during sexual activity, and dysuria.7 
A population-based data survey study conducted in the 
UK also showed that men with a diagnosis of LUTS had a 
significantly increased prevalence of all kinds of sexual 
dysfunction compared with men without LUTS, and a di-
agnosis of LUTS even preceded the diagnosis of sexual 
dysfunction in a majority of men.8
2.2.  Nitric Oxide/Cyclic Guanosine 
Monophosphate—A Common Mechanism of 
ED and LUTS
Although there are strong links between ED and LUTS 
based on epidemiologic evidence, the exact mechanisms 
are still unclear. Smooth muscle tone and function may 
play important roles in both erection function and urinary 
bladder physiology. Since the discovery of nitric oxide (NO) 
as the major nonadrenergic noncholinergic neurotrans-
mitter in penile erection, the NO/cyclic guanosine mono-
phosphate (cGMP) pathway with an inhibitory effect on 
smooth muscles and nerves of the lower urinary tract 
(LUT) was postulated as one of the major component in 
urination control.9–11 NO-mediated smooth muscle re-
laxation was also demonstrated in the human bladder 
neck, trigone, sphincter, and prostate.12,13 LUT smooth 
muscles can be relaxed by drugs that increase the intra-
cellular concentrations of cyclic adenosine monophosphate 
(cAMP) and cGMP. In LUT smooth muscles, increases in 
cAMP seem to play a major role in bladder relaxation, 
whereas cGMP is more important for urethral relaxa-
tion.14,15 Furthermore, NO released from the uro thelium 
was implicated in suppressing excitatory signals from ad-
jacent afferent nerves. On the other hand, overexpression 
of NO synthase and increased release of NO from the uro-
thelium were found in an animal model with interstitial 
cystitis, which might be attributed to bladder overactiv-
ity induced by inflammation.16,17 Interestingly, systemic 
administration of 20 mg of isosorbide dinitrate as an NO 
donor sublingually in 11 healthy volunteers in a pressure 
flow study produced a decreased in the average detrusor 
pressure during micturition of 57 to 52 cmH2O, while the 
average uroflow rate increased from 16.7 to 20.2 mL/s. 
The authors concluded that systemic NO administration 
can lower the functional bladder outlet resistance in men, 
and the NO/cGMP pathway might be a promising target 
for medical treatment of LUTS.18 In addition to the NO/
cGMP pathway, there are other possible mechanisms, in-
cluding pelvic atherosclerosis/ischemia, the autonomic 
hyperactivity/metabolic syndrome hypo thesis and the 
Rho-kinase activation/endothelin pathway, which might 
explain the relationship between ED and LUTS/BPH.19,20
3.  Distribution of Phosphodiesterases (PDEs) 
in the LUT
PDEs, a heterogeneous group of hydrolytic enzymes, in-
activate the cAMP and cGMP intracellular signals and are 
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involved in smooth muscle tone regulation. In total, 11 
distinct families with 21 human genes were identified 
based on their amino acid sequences, cyclic nucleotide 
substrates, and catalytic considerations.21
PDE1, -2, -3, -4, -5 and -9 were identified in the human 
urinary bladder.22 Werkstrom et al.23 characterized the 
distributions of PDE5 and cGMP in the human urethra, 
and the smooth muscle relaxant effect was associated 
with increased levels of cGMP.
Almost all of the PDEs found in the human prostate are 
highly expressed as the PDE9A and PDE11A isoforms.14 
Secondary messengers including cGMP and cAMP were 
found to be involved in the control of the normal func-
tion of the prostate. Uckert et al.24 further demonstrated 
by an immunohistologic method the presence of PDE4 
in the fibromuscular stroma of the prostate as well as in 
glandular structures of the transition zone. In contrast to 
the distribution of PDE4, the presence of PDE5 and PDE11 
was mainly observed in glandular and stromal regions.24 
The presence and functional relevance of PDE isoen-
zymes 1, 4, and 5 in human prostatic tissue support the 
possible use of inhibitors of PDE1, -4, and -5 to treat uri-
nary obstruction secondary to BPH.11,25–27
An in vitro prostate tissue study also confirmed that 
PDE4 and -5 inhibitors can reverse the tension induced 
by norepinephrine, and the most prominent enhance-
ment in tissue cGMP levels could be significantly ele-
vated by tadalafil, vardenafil and sildenafil to different 
degrees (28-fold, 12-fold and threefold, respectively).28 
Treatment with selective PDE4 inhibitors showed their 
ability to reduce bladder overactivity and to suppress ex-
perimental bladder inflammation in animal studies.29,30 
Recently, Bittencourt et al.13 further confirmed that sil-
denafil was effective in inducing bladder neck smooth 
muscle relaxation in vitro, and this effect could be abol-
ished by Nω-nitro-L-arginine methyl ester (L-NAME), which 
further indicated the dependence of the NO/cGMP path-
way in the bladder neck.
4.  Clinical Results of PDE5 Inhibitors for 
LUTS Treatment
Different kinds of PDE1, -4 and -5 inhibitors were used to 
verify their effectiveness in treating LUTS. In a pilot study 
using the PDE1 inhibitor, vinpocetine, 11 of 19 patients 
(57.9%) with urge incontinence and a low-compliance 
bladder and who were nonresponders to standard phar-
macologic therapy showed improvements in clinical symp-
toms and/or urodynamic parameters.31
With the extensive use of PDE5 inhibitors in the treat-
ment of male ED since 1998, more clinical data show 
that PDE5 inhibitors appear to improve erectile function 
as well as urinary symptom scores. In an observational, 
nonrandomized study conducted in 2002 which enrolled 
112 male patients for ED treatment, concomitant Inter-
national Prostate Symptom Score (IPSS) evaluations after 
1–3 months of sildenafil treatment showed a trend towards 
improvements in the IPSS. A lower IPSS at the baseline 
appeared to predict a better response to sildenafil.32 In 
another open-label study, 48 men (with a mean age of 62 
years) with ED and an IPSS of ≥ 10 were enrolled to receive 
on-demand sildenafil citrate treatment for 3 months. 
About 60% of these men showed an improvement in 
their IPSS with a mean 4.6-point reduction, but only 35% 
of them had more than a 4-point improvement.33 In a 
double-blind, placebo-controlled trial in 25 patients with 
spinal cord injury who had ED and micturition disorders, 
a urodynamic study done 1–3 hours after the oral ad-
ministration of 20 mg of vardenafil showed an increased 
bladder capacity (253 vs. 296 mL; p = 0.004) and reduced 
maximal detrusor pressure (57 vs. 52 cmH2O; p = 0.039).34
Furthermore significant improvements in LUTS were 
demonstrated in several large, multicenter, randomized, 
placebo-controlled trials (Table 1).35–41 However, most 
of those studies showed that PDE5 inhibitors could only 
improve the irritative or obstructive symptoms based on 
IPSS reduction but had little effect on uroflowmetric pa-
rameters or the post-voiding residual volume. The com-
bined use of PDE5 inhibitors and α-blockers seems to 
have more-promising results than monotherapy alone in 
terms of IPSS reduction or mean maximal uroflow rate 
(Qmax) improvement. One possible explanation for this 
poor uroflow rate response with PDE5 inhibitors alone 
may be the predominant effects of non-voiding contrac-
tions by these PDE5 inhibitors.27 Aging, the static com-
ponent of the prostate in bladder outlet obstruction, 
sympathetic tone overactivity, and androgen-dependent 
PDE5 inhibitor activity were cited as possible factors in-
fluencing the responses.11,42–45
5.  Safety Concerns About Combined Therapy 
With a-Blockers
The concurrent reduction of the sympathetic tone within 
the LUT by α-blockers and inhibition of prostate growth 
by 5α-reductase inhibitors are still the main strategy in 
medical management of LUTS/BPH.
Although early clinical results showed the potential 
of using PDE5 inhibitors to improve LUTS/BPH, the safety 
profiles of the combined use of α-blockers and PDE5 in-
hibitors in LUTS/BPH treatment are not well established. 
According to the label information, none of the three 
PDE5 inhibitors should be taken with α-blockers other 
than tamsulosin because of the risk of adverse vasodila-
tory events.46 However, a randomized placebo-controlled 
study confirmed the safety and efficacy of the combined 
use of 4 mg of doxazosin daily and 100 mg of sildenafil 
on-demand for treating non-organic ED men who were 
sildenafil nonresponders.47 A similar hemodynamic eval-
uation was conducted in 16 men with BPH, and the blood 
pressure was measured in both the supine and passive 
orthostatic positions after 0.4 mg of tamsulosin daily for 
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14 days and a single dose of 100 mg of sildenafil or a pla-
cebo. The authors confirmed that the combined use of 
tamsulosin and sildenafil decreased the systemic blood 
pressure and vascular resistance index in the supine 
position.48
The safety of the combined use of alfuzosin and 
tadalafil was evaluated in a randomized, double-blind, 
placebo-controlled, crossover study. Eighteen healthy vol-
unteers who received 10 mg of alfuzosin daily for 7 days 
were randomized to receive on-demand 20 mg of tadala-
fil or a placebo on the 7th day. Only a 4-mmHg differ-
ence in the standing systolic blood pressure was noted 
between the tadalafil and placebo groups.49 Recently, in 
a randomized, double-blind, placebo-controlled, crossover 
study, 38 patients with BPH and ED, who were treated 
with 4 mg of doxazosin (67.6%) daily or 8 mg (32.4%) on 
a regular basis, were enrolled. The standing and supine 
blood pressures were measured 1 hour before and 
6 hours after the administration of 10 mg of vardenafil. 
A maximal decrease in systolic pressure of 6.18 mmHg in 
the standing position was found with the combined use 
of doxazosin and vardenafil. The authors concluded that 
a single dose of 10 mg of vardenafil had no hypotensive 
effects on patients receiving regular doxazosin treatment.50 
Although there are usually small additive re ductions in 
blood pressure without significant adverse events, some 
patients may still develop orthostatic hypotension when 
these PDE5 inhibitors are used in patients receiving 
regular α-blocker treatment. Precautions are necessary 
for all three PDE5 inhibitors regarding this potential 
interaction.51
6. Conclusion
Men with a diagnosis of LUTS have a significantly in-
creased prevalence of all kinds of sexual dysfunction 
compared with those men without LUTS. The NO/cGMP 
pathway, which has an inhibitory effect on smooth mus-
cles and nerves of the LUT, is postulated to be one of 
the major components in their regulation. Early rando-
mized clinical studies showed that daily dosing with 
PDE5 inhibitors could improve the irritative or obstructive 
symptoms based on IPSS reduction but had little effect 
on uroflowmetric parameters or post-voiding residuals. 
The combined use of PDE5 inhibitors and α-blockers 
showed more-promising results, but the safety concerns 
of this combined use should be further evaluated and 
confirmed by additional randomized and comparative 
clinical studies.
Table 1  Summary of recent randomized clinical studies for phosphodiesterase type 5 inhibitors in treating lower urinary tract 
symptoms associated with benign prostatic hyperplasia
  Mean IPSS Qmax (mL/s)
Author (publication year) Arm/drug (no. of patients) 
Baseline Week 12 Change Baseline Week 12 Change
McVary et al.35 (2007) Placebo (180) – – −1.93 – – +0.16
 Sildenafil 50 or 100 mg qd (189) – – −6.32* – – +0.31
McVary et al.36 (2007) Placebo (143) 18.3 16.1 −1.7 11.1 12.1 +1.0
 Tadalafil 5 or 20 mg qd (138) 17.5 13.3 −3.8* 11.8 12.3 +0.5
Stief et al.38 (2008) Placebo (113) 16.8 13.2 −3.6 15.9 16.9 +1.0
 Vardenafil 10 mg bid (108) 16.8 11.0 −5.8* 15.9 17.5 +1.6
Roehrborn et al.39 (2008) Placebo (212) – – −2.27 – – +1.24
 Tadalafil 2.5 mg qd (209) – – −3.88* – – +1.41
 5 mg qd (212) – – −4.87* – – +1.64
 10 mg qd (216) – – −5.17* – – +1.58
 20 mg qd (209) – – −5.21* – – +1.96
Kaplan et al.37 (2007) Alfuzosin 10 mg qd (20) 17.3 14.6 −2.7* 9.4 10.5 +1.1*
 Sildenafil 25 mg qd (21) 16.9 14.9 −2.0* 9.7 10.3 +0.6
 Combination (21) 17.8 13.5 −4.3* 9.5 11.5 +2.0*
Bechara et al.40 (2008) Tamsulosin 0.4 mg qd +  19.4 12.7 −6.7* 9.6 11.7 +2.1
  placebo (30)
 Tamsulosin 0.4 mg qd + tadalafil 19.4 10.2 −9.2* 9.6 12.6 +3.0
  20 mg qd (30)
Liguori et al.41 (2009)  Alfuzosin 10 mg qd (18) 15.7 10.5 −5.2* 12.3 14.0 +1.7*
 Tadalafil 20 mg qod (19) 13.8 12.5 −1.3 13.1 14.3 +1.2*
 Combination (21) 15.3  9.0 −6.3* 11.9 15.0 +3.1*
*p < 0.05. IPSS = International Prostate Symptom Score; Qmax = mean maximal uroflow rate; – = not available; qd = everyday; bid = twice a day; 
qod = every other day.
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